The UK Medicines and Healthcare products Regulatory Agency (MHRA) has a long history as a valued contributor to the global regulatory ecosystem. This contribution has been realised not only through advancements in regulatory science, but also through acting as a point of reference for the regulatory decision-making of other regulators and by leveraging outcomes from trusted partners in the system to deliver regulatory decisions and facilitate access to innovative medicines for UK patients. This balance of acting as a reference and recognising expert outputs from others is now widely accepted as standard practice and can in fact be seen as a measure of regulatory maturity. We believe that this balance should be retained as a central part of the MHRA’s operating model moving forward.
In this blog, Jaime Eaton, reflects on this month's Community Connects series, bringing together diverse expertise to tackle the most pressing challenges in our sector.
The launch of the NIHR Industry hub last week, the launch of UKRI/Innovate strategy this Thursday and a landmark Mansion House event tomorrow all signal forward momentum on Industrial Strategy.
